Moreover, ST6GAL1 endows resistance of cancer cells to gefitinib (EGFR inhibitor) and trastuzumab (anti-ErbB2 antibody) and also predicts the sensitivity of lenvatinib treatment to patients with hepatocellular carcinoma (25). Here, ERBB2 is linked to cancer.